Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010

Journal of Microbiology, Immunology and Infection

Volumn 47, Issue 2, 2014, Pages 95-103

  Chen, Pao Yu ^a   Chuang, Yu Chung ^a   Wang, Jann Tay ^a   Sheng, Wang Huei ^a   Yu, Chung Jen ^a,b   Chu, Chen Chen ^a   Hsueh, Po Ren ^a   Chang, Shan Chwen ^a,b   Chen, Yee Chun ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Candidemia; Disease severity; Epidemiology; Outcome; Surveillance

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDA; CANDIDEMIA; CHARLSON COMORBIDITY INDEX; CHILD; CHRONIC LUNG DISEASE; COMPARATIVE STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INCIDENCE; INFANT; INFECTION CONTROL; KIDNEY DISEASE; LENGTH OF STAY; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SPECIES DISTRIBUTION; TAIWAN; TEACHING HOSPITAL; TREATMENT OUTCOME; YOUNG ADULT;

CANDIDEMIA; DISEASE SEVERITY; EPIDEMIOLOGY; OUTCOME; SURVEILLANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; FEMALE; HOSPITALS, TEACHING; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897025942     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.08.025     Document Type: Article

References (41)

1. Rentz A.M., Halpern M.T., Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27:781-788.
2. Sheng W.H., Wang J.T., Lu D.C., Chie W.C., Chen Y.C., Chang S.C. Comparative impact of hospital-acquired infections on medical costs, length of hospital stay and outcome between community hospitals and medical centres. J Hosp Infect 2005, 59:205-214.
3. Tseng S.H., Lee C.M., Lin T.Y., Chang S.C., Chuang Y.C., Yen M.Y., et al. Combating antimicrobial resistance: antimicrobial stewardship program in taiwan. J Microbiol Immunol Infect 2012, 45:79-89.
4. Beck-Sague C., Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the united states, 1980-1990. National nosocomial infections surveillance system. J Infect Dis 1993, 167:1247-1251.
5. Marchetti O., Bille J., Fluckiger U., Eggimann P., Ruef C., Garbino J., et al. Epidemiology of candidemia in swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004, 38:311-320.
6. Chuang Y.C., Chen Y.C., Chang S.C., Sun C.C., Chang Y.Y., Chen M.L., et al. Secular trends of healthcare-associated infections at a teaching hospital in taiwan, 1981-2007. J Hosp Infect 2010, 76:143-149.
7. Liu C.Y., Liao C.H., Chen Y.C., Chang S.C. Changing epidemiology of nosocomial bloodstream infections in 11 teaching hospitals in taiwan between 1993 and 2006. J Microbiol Immunol Infect 2010, 43:416-429.
8. Chen Y.C., Chang S.C., Sun C.C., Yang L.S., Hsieh W.C., Luh K.T. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997, 18:369-375.
9. Hung C.C., Chen Y.C., Chang S.C., Luh K.T., Hsieh W.C. Nosocomial candidemia in a university hospital in taiwan. J Formos Med Assoc 1996, 95:19-28.
10. Chen Y.C., Chang S.C., Luh K.T., Hsieh W.C. Stable susceptibility of candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003, 52:71-77.
11. Chen Y.C., Sheng W.H., Wang J.T., Chang S.C., Lin H.C., Tien K.L., et al. Effectiveness and limitations of hand hygiene promotion on decreasing healthcare-associated infections. PLoS ONE 2011, 6:e27163.
12. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. Cdc definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16:128-140.
13. Horan T.C., Andrus M., Dudeck M.A. Cdc/nhsn surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
14. Chen Y.C., Chang S.C., Tai H.M., Hsueh P.R., Luh K.T. Molecular epidemiology of candida colonizing critically ill patients in intensive care units. J Formos Med Assoc 2001, 100:791-797.
15. Hsueh P.R., Chen M.L., Sun C.C., Chen W.H., Pan H.J., Yang L.S., et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in taiwan, 1981-1999. Emerg Infect Dis 2002, 8:63-68.
16. Lai C.C., Wang C.Y., Liu W.L., Huang Y.T., Hsueh P.R. Time to positivity of blood cultures of different candida species causing fungaemia. J Med Microbiol 2012, 61:701-704.
17. Chiu Y.S., Chang S.C., Hsueh P.R., Wang J.L., Sun H.Y., Chen Y.C. Survey of amphotericin b susceptibility of candida clinical isolates determined by etest. J Microbiol Immunol Infect 2006, 39:335-341.
18. Wang J.L., Chang S.C., Hsueh P.R., Chen Y.C. Species distribution and fluconazole susceptibility of candida clinical isolates in a medical center in 2002. J Microbiol Immunol Infect 2004, 37:236-241.
19. Golan Y., Wolf M.P., Pauker S.G., Wong J.B., Hadley S. Empirical anti-candida therapy among selected patients in the intensive care unit: A cost-effectiveness analysis. Ann Intern Med 2005, 143:857-869.
20. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
21. Garbino J., Kolarova L., Rohner P., Lew D., Pichna P., Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 2002, 81:425-433.
22. Playford E.G., Nimmo G.R., Tilse M., Sorrell T.C. Increasing incidence of candidaemia: long-term epidemiological trends, queensland, australia, 1999-2008. J Hosp Infect 2010, 76:46-51.
23. Ota K.V., McGowan K.L. Declining incidence of candidemia in a tertiary inpatient pediatric population. J Clin Microbiol 2012, 50:1048-1050.
24. Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R. Candidaemia in europe: epidemiology and resistance. Int J Antimicrob Agents 2006, 27:359-366.
25. Dutta A., Palazzi D.L. Candida non-albicans versus candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 2011, 30:664-668.
26. Pittet D., Wenzel R.P. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995, 155:1177-1184.
27. Nucci M., Queiroz-Telles F., Tobon A.M., Restrepo A., Colombo A.L. Epidemiology of opportunistic fungal infections in latin america. Clin Infect Dis 2010, 51:561-570.
28. Sifuentes-Osornio J., Corzo-Leon D.E., Ponce-de-Leon L.A. Epidemiology of invasive fungal infections in latin america. Curr Fungal Infect Rep 2012, 6:23-34.
29. Chen L.Y., Liao S.Y., Kuo S.C., Chen S.J., Chen Y.Y., Wang F.D., et al. Changes in the incidence of candidaemia during 2000-2008 in a tertiary medical centre in northern taiwan. J Hosp Infect 2011, 78:50-53.
30. Kao A.S., Brandt M.E., Pruitt W.R., Conn L.A., Perkins B.A., Stephens D.S., et al. The epidemiology of candidemia in two united states cities: results of a population-based active surveillance. Clin Infect Dis 1999, 29:1164-1170.
31. Poikonen E., Lyytikainen O., Anttila V.J., Ruutu P. Candidemia in finland, 1995-1999. Emerg Infect Dis 2003, 9:985-990.
32. Poikonen E., Lyytikainen O., Anttila V.J., Koivula I., Lumio J., Kotilainen P., et al. Secular trend in candidemia and the use of fluconazole in finland, 2004-2007. BMC Infect Dis 2010, 10:312-320.
33. Asmundsdottir L.R., Erlendsdottir H., Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in iceland. J Clin Microbiol 2002, 40:3489-3492.
34. Spellberg B.J., Filler S.G., Edwards J.E. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006, 42:244-251.
35. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
36. Pfaller M.A., Pappas P.G., Wingard J.R. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006, 43:S3-S14.
37. Marriott D.J., Playford E.G., Chen S., Slavin M., Nguyen Q., Ellis D., et al. Determinants of mortality in non-neutropenic icu patients with candidaemia. Crit Care 2009, 13:R115.
38. Kludze-Forson M., Eschenauer G.A., Kubin C.J., Della-Latta P., Lam S.W. The impact of delaying the initiation of appropriate antifungal treatment for candida bloodstream infection. Med Mycol 2010, 48:436-439.
39. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrobial Agents Chemother 2005, 49:3640-3645.
40. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006, 43:25-31.
41. Andes D.R., Safdar N., Baddley J.W., Playford G., Reboli A.C., Rex J.H., et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012, 54:1110-1122.